Pakistan’s pharmaceutical exports hit 34% growth in FY25, marking a two-decade high

Exports of locally produced medicines reach $457 million, with deregulation policy boosting growth

Pakistan’s pharmaceutical sector has achieved 34% growth in exports during the fiscal year ended June 30, 2025, reaching $457 million. This surge marks the highest growth in two decades and places pharmaceuticals among the country’s fastest-growing export categories. 

The previous year, pharmaceutical exports were recorded at $341 million. The growth is the most significant since 2009, when exports grew by 32%. 

Therapeutic goods, including pharmaceuticals, surgicals, food supplements, medical devices, and nutraceuticals, also registered significant export figures, totaling $909 million in FY25, just $91 million short of the $1 billion mark.

The Pakistan Pharmaceutical Manufacturers’ Association (PPMA) attributed the 34% export growth to favourable government pricing policies. The association noted that the deregulation of non-essential medicines in February 2024 allowed pharmaceutical firms to focus on exports, adjust for inflation, invest in production, and curb black-market sales.

The deregulation also encouraged foreign pharmaceutical companies to invest further in Pakistan, leading to a positive outlook for long-term market stability. 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Must Read

Ecnec approves construction of two major road projects in Balochistan 

Committee chaired by Ishaq Dar clears 103 km Zhob–Murgha Kabza and 105 km Duki–Chamalang roads; five-year Balochistan education project also reviewed